

Date 02/05/2025  
Your Ref  
Our Ref 9952

Enquiries to Richard Mutch  
Extension 35687  
Direct Line 0131 465 5687  
[loth.freedomofinformation@nhs.scot](mailto:loth.freedomofinformation@nhs.scot)  
[richard.mutch@nhs.scot](mailto:richard.mutch@nhs.scot)

Dear

## FREEDOM OF INFORMATION – PROSTATE CANCER

I write in response to your request for information in relation to prostate cancer.

### Question:

- For each of the following hormone therapies used to treat prostate cancer, please provide the number of patients treated at your Trust between 01 January and 31 December (by years 2023 and 2024). For each therapy, broken down the data into the following categories:
  - Total Number of Patients Treated for ICD-10 C61 / M1-M1c (metastatic)
  - Number of Patients for Whom Hormone Therapy Was Initiated for ICD-10 C61 / M1-M1c (metastatic)
  - Number of Patients for Whom Hormone Therapy Was Continued; ICD-10 C61 / M1-M1c (metastatic)
  - Number of patients for whom docetaxel was initiated for ICD-10 C61 / M1-M1c (localised & metastatic)
- The hormone therapies of interest are:
  - ADT alone
  - Abiraterone (Zytiga) in combination with any ADT
  - Abiraterone (Zytiga) – no ADT
  - Enzalutamide (Xtandi) in combination with any ADT
  - Enzalutamide (Xtandi) – no ADT
  - Apalutamide (Erleada) in combination with any ADT
  - Darolutamide (Nubeqa) in combination with any ADT
  - Darolutamide (Nubeqa) in combination with any ADT with docetaxel
  - Docetaxel in combination with any ADT
- Total number of patients in each year, for each therapy for whom:
  - Hormone therapy was initiated
  - Hormone therapy was continued
  - Docetaxel was initiated

Headquarters  
Mainpoint  
102 West Port  
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE  
Chief Executive Professor Caroline Hiscox  
*Lothian NHS Board is the common  
name of Lothian Health Board*

Answer:

DRUGNAME	Total 2023	Total 2024	New 2023	New 2024	Continued 2023	Continued 2024
ABIRATERONE	199	220	59	68	140	152
APALUTAMIDE	5<	5<	5<	5<	5<	5<
DAROLUTAMIDE	5<	5<	5<	5<	0	5<
DOCETAXEL	5<	5<	5<	5<	5<	5<
ENZALUTAMIDE	105	151	47	67	58	84
Data on treatment alongside ADTs cannot be provided - requires linkage between multiple data sets. Under the Freedom of Information Act NHS Lothian is not required to create new records to enable it to respond to your enquiry. This information is not collated or held in aggregate form and it would be necessary to review all case files <b>relating to patients</b> over the period you have requested to assemble the information you seek. Even if NHS Lothian did this – and there would be significant cost implications in doing so – it would be unable to respond in full to your request. The information requested is therefore exempt under section 12.1 – Cost.						

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the table above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at [www.itspublicknowledge.info/Appeal](http://www.itspublicknowledge.info/Appeal). If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

**ALISON MACDONALD**  
**Executive Director, Nursing**  
Cc: Chief Executive